Skip to main navigation Skip to search Skip to main content

Activation of 2,4-Diaminoquinazoline in Mycobacterium tuberculosis by Rv3161c, a Putative Dioxygenase

  • Eduard Melief
  • , Shilah A. Bonnett
  • , Edison S. Zuniga
  • , Tanya Parish
  • Infectious Disease Research Institute

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

The diaminoquinazoline series has good potency against Mycobacterium tuberculosis. Resistant isolates have mutations in Rv3161c, a putative dioxygenase. We carried out metabolite analysis on a wild-type strain and an Rv3161c mutant strain after exposure to a diaminoquinazoline. The parental compound was found in intracellular extracts from the mutant but not the wild type. A metabolite consistent with a monohydroxylated form was identified in the wild type. These data support the hypothesis that Rv3161c metabolizes diaminoquinazolines in M. tuberculosis.

Original languageEnglish
Article numbere01505-18
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number1
DOIs
Publication statusPublished - 21 Dec 2018
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antitubercular
  • Diaminoquinazoline
  • Dioxygenases
  • Monooxygenases
  • Mycobacterium tuberculosis
  • Prodrug

Fingerprint

Dive into the research topics of 'Activation of 2,4-Diaminoquinazoline in Mycobacterium tuberculosis by Rv3161c, a Putative Dioxygenase'. Together they form a unique fingerprint.

Cite this